GA-SYNCRON
27.9.2021 15:04:10 CEST | Business Wire | Press release
Syncron, the largest privately-owned global leader in intelligent SaaS solutions dedicated to End-to-End Continuous Service LifeCycle Management, announced today that it has been named a Leader in the IDC MarketScape: Worldwide B2B Price Optimization and Management Applications 2021 Vendor Assessment (doc # US46742021, September 2021). Syncron is providing a complimentary excerpt of the IDC MarketScape report here .
The IDC MarketScape vendor assessment model is an important competitive evaluation and scoring of the SaaS-based business-to-business price optimization and management solution suppliers available in the global market. According to the IDC MarketScape the nine vendors covered in the IDC MarketScape represent the front-runners and the vendors most representative of any given B2B PO&M application buyer's selection short list. IDC’s research methodology uses a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear, customer influenced framework, in which the product and service offerings, capabilities, and strategies, and current and future market success factors can be meaningfully compared.
The IDC MarketScape report’s profile stated, “After a thorough evaluation of Syncron's offerings and capabilities, IDC has positioned the company in the Leaders category within this 2021 IDC MarketScape for B2B price optimization and management applications.” The report also states that “Syncron has greatly expanded its vision to be the end-to-end service management provider. This is an integrated suite of solutions to optimize inventory, price, and uptime for aftermarket parts and service for B2B or retail-focused companies. This enables Syncron to optimize both price and cost.”
The research positioned Syncron as a leader based on the flexible capabilities and intuitive functionality of Syncron Price, and the company’s deep understanding of the aftermarket industry globally.
The report states that companies should consider Syncron when they’re in the aftermarket service industry and need an end-to-end service management solution with integrated pricing. The IDC MarketScape vendor assessment also recognized three of Syncron’s strengths:
Deep understanding of aftermarket service management: Syncron Price benefits from Syncron Inventory and the company's deep institutional knowledge of the cost side of the equation to manage profit when pricing inventory that is deployed around the world, including location (delivery time, taxes, tariffs), age, and scarcity/replacement value. Customers highly appreciated this experience to set up personalized pricing for specialty parts and kits.
Ease of Use: Customers highly rated Syncron for how easy the product was to learn and use. They liked that it had initiative workflows that were "one to two clicks away from done."
Pricing Agility: Syncron makes it easy to segment and manage huge numbers of parts. Customers liked the ML-driven segmentation workflow that made segmentation easy to implement and gave the user the best choices of which segment the product should be placed in. One customer was managing 300,000 parts with one person while being able to reprice each on a far more regular basis with greater profit.
“Syncron combines its deep knowledge of the global aftermarket industries, with robust solution capabilities, and expert services to substantively increase the efficiency and profitability of an OEM's aftermarket businesses,” says Mark Thomason, Research Director, IDC. “Syncron Price enables manufacturers, dealers, and suppliers to automate and optimize dynamic pricing capabilities, quickly and globally. By leveraging artificial intelligence and machine learning, Syncron Price can segment highly complex product lists and identify otherwise unseen revenue uplift and margin opportunities.”
“At Syncron, we’re committed to empower the world’s leading manufacturers and distributors to drive profitable business and competitive advantage by providing intelligent and connected service experience solutions. We are deeply honored the IDC MarketScape named Syncron a Leader for the Price Optimization and Management category. This acknowledgement follows similar IDC MarketScape recognitions of Syncron and its newly acquired company, Mize, in the areas of Field Service Management (FSM)1 , Service Parts Management (SPM), and Warranty Contract Management (WCM)2 ,” said Dr. Friedrich Neumeyer, CEO of Syncron. “Being recognized as a leader in multiple strategic categories by the IDC MarketScape is validation that our significant innovation investments in AI and ML innovation, user experience, architectural extensibility, scalability, security, and platform are quickly paying dividends. It also echoes Syncron’s nonstop passion and commitment and ability to execute our customers’ success.”
To learn more about Syncron Price, www.syncron.com/price .
About Syncron
Syncron accelerates leading manufacturers and distributors to capitalize on the world's new service economy. We improve aftermarket business profitability, optimize working capital, increase customer loyalty, and enable our customer’s ability to transition successfully to future service-driven business models. With our industry-leading investments in AI and ML, Syncron offers the first, innovative, customer-endorsed, and complete end-to-end intelligent Service Lifecycle Management solution portfolio. Syncron’s offer encompasses leadership solutions such as: service parts inventory, price, equipment uptime, warranty, service contract, and field service management. Delivered on Syncron’s Connected Service Experience (CSX) platform, our solutions offer our customers competitive differentiation through exceptional aftermarket service experiences, while simultaneously driving significant revenue and profit improvements into a manufacturer or distributor’s business. It is no secret that world's top brands trust Syncron, making it the largest privately-owned global leader in intelligent SLM SaaS solutions. For more information, visit syncron.com .
1 IDC MarketScape: Worldwide Manufacturing Field Service Management Applications 2019–2020 Vendor Assessment, Aly Pinder, IDC #US44408719, November 2019
2 IDC MarketScape: Worldwide Manufacturing Warranty and Service Contract Management Applications 2019–2020 Vendor Assessment, Aly Pinder, IDC# US44408619 December 2019
View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005247/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom